PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-90.13%
Negative revenue growth while GNPX stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-148.93%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-24.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-24.71%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-23.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-23.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.68%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1874.89%
Negative 10Y OCF/share CAGR while GNPX stands at 48.75%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
89.77%
5Y OCF/share CAGR above 1.5x GNPX's 48.75%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
79.09%
3Y OCF/share CAGR above 1.5x GNPX's 50.76%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-5123.81%
Negative 10Y net income/share CAGR while GNPX is at 23.14%. Joel Greenblatt sees a major red flag in long-term profit erosion.
89.73%
5Y net income/share CAGR above 1.5x GNPX's 23.14%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
77.51%
3Y net income/share CAGR above 1.5x GNPX's 47.76%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1605.51%
10Y equity/share CAGR above 1.5x GNPX's 243.32%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-64.94%
Negative 5Y equity/share growth while GNPX is at 243.32%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
48.08%
3Y equity/share CAGR similar to GNPX's 46.63%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.40%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-26.37%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
15.04%
R&D dropping or stable vs. GNPX's 143.04%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
33.15%
SG&A growth well above GNPX's 9.76%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.